Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 October 1995:
Vol. 270. no. 5235, pp. 475 - 480
DOI: 10.1126/science.270.5235.475
Prev | Table of Contents | Next

Reports

T Lymphocyte-Directed Gene Therapy for ADA SCID: Initial Trial Results After 4 Years

R. Michael Blaese (1),  Kenneth W. Culver,  A. Dusty Miller,  Charles S. Carter,  Thomas Fleisher,  Mario Clerici (2),  Gene Shearer,  Lauren Chang,  Yawen Chiang,  Paul Tolstoshev,  Jay J. Greenblatt,  Steven A. Rosenberg,  Harvey Klein,  Melvin Berger,  Craig A. Mullen (3),  W. Jay Ramsey,  Linda Muul,  Richard A. Morgan,  W. French Anderson (4)

In 1990, a clinical trial was started using retroviral-mediated transfer of the adenosine deaminase (ADA) gene into the T cells of two children with severe combined immunodeficiency (ADA SCID). The number of blood T cells normalized as did many cellular and humoral immune responses. Gene treatment ended after 2 years, but integrated vector and ADA gene expression in T cells persisted. Although many components remain to be perfected, it is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.


R. M. Blaese, C. A. Mullen, W. J. Ramsey, National Center for Human Genome Research, National Institutes of Health (NIH), Building 49, Room 2A03, Bethesda, MD 20892, USA, and National Cancer Institute (NCI), NIH, Bethesda, MD 20892, USA.
K. W. Culver, M. Clerici, G. Shearer, J. J. Greenblatt, S. A. Rosenberg, NCI, NIH, Bethesda, MD 20892, USA.
A. D. Miller, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
C. S. Carter, T. Fleisher, H. Klein, Clinical Center, NIH, Bethesda, MD 20892, USA.
L. Chang and W. F. Anderson, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD 20892, USA.
Y. Chiang and P. Tolstoshev, Genetic Therapy, Gaithersburg, MD 20878, USA.
M. Berger, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
L. Muul, National Center for Human Genome Research, NIH, Bethesda, MD 20892, USA.
R. A. Morgan, National Center for Human Genome Research, NIH, Bethesda, MD 20892, USA, and NHLBI, NIH, Bethesda, MD 20892, USA.
(1) To whom correspondence should be addressed at the National Center for Human Genome Research. E-mail:mblaese{at}nchgr.nih.gov
(2) Present address: Cattedra Di Immunogia, Universita Milano, Milan 20133, Italy.
(3) Present address: Division of Pediatrics, M. D. Anderson Cancer Center, Houston, TX 77030, USA.
(4) Present address: Norris Cancer Center, University of Southern California School of Medicine, Los Angeles, CA 90033, USA.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
How I treat ADA deficiency.
H. B. Gaspar, A. Aiuti, F. Porta, F. Candotti, M. S. Hershfield, and L. D. Notarangelo (2009)
Blood 114, 3524-3532
   Abstract »    Full Text »    PDF »
Lack of specific {gamma}-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.
W. R. Burns, Z. Zheng, S. A. Rosenberg, and R. A. Morgan (2009)
Blood 114, 2888-2899
   Abstract »    Full Text »    PDF »
Gene Therapy and Informed Consent Decision Making: Nursing Research Directions.
R. W. Kaspar, C. E. Wills, and B. K. Kaspar (2009)
Biol Res Nurs 11, 98-107
   Abstract »    PDF »
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency.
A. Aiuti, F. Cattaneo, S. Galimberti, U. Benninghoff, B. Cassani, L. Callegaro, S. Scaramuzza, G. Andolfi, M. Mirolo, I. Brigida, et al. (2009)
N. Engl. J. Med. 360, 447-458
   Abstract »    Full Text »    PDF »
Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins.
C. Frecha, C. Costa, D. Negre, E. Gauthier, S. J. Russell, F.-L. Cosset, and E. Verhoeyen (2008)
Blood 112, 4843-4852
   Abstract »    Full Text »    PDF »
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection.
C. C. Porter and J. DeGregori (2008)
Blood 112, 4466-4474
   Abstract »    Full Text »    PDF »
Development of gene therapy for blood disorders.
A. W. Nienhuis (2008)
Blood 111, 4431-4444
   Abstract »    Full Text »    PDF »
An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
B. Y. Ryu, M. V. Evans-Galea, J. T. Gray, D. M. Bodine, D. A. Persons, and A. W. Nienhuis (2008)
Blood 111, 1866-1875
   Abstract »    Full Text »    PDF »
In situ oligonucleotide synthesis on carbon materials: stable substrates for microarray fabrication.
M. F. Phillips, M. R. Lockett, M. J. Rodesch, M. R. Shortreed, F. Cerrina, and L. M. Smith (2008)
Nucleic Acids Res. 36, e7
   Abstract »    Full Text »    PDF »
Update on clinical gene therapy in childhood.
W. Qasim, H Bobby Gaspar, and A. J Thrasher (2007)
Arch. Dis. Child. 92, 1028-1031
   Abstract »    Full Text »    PDF »
Molecular basis of hematology.
M. P. Mims and J. T. Prchal (2007)
ASH Self-Assessment Program 2007, 1-22
   Full Text »    PDF »
The Yin and Yang of Stem Cell Gene Therapy: Insights into Hematopoiesis, Leukemogenesis, and Gene Therapy Safety.
C. E. Dunbar (2007)
Hematology 2007, 460-465
   Abstract »    Full Text »    PDF »
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.
A. Mortellaro, R. J. Hernandez, M. M. Guerrini, F. Carlucci, A. Tabucchi, M. Ponzoni, F. Sanvito, C. Doglioni, C. D. Serio, L. Biasco, et al. (2006)
Blood 108, 2979-2988
   Abstract »    Full Text »    PDF »
Stereotactic Coregistration of 201Tl SPECT and MRI Applied to Brain Tumor Biopsies.
S. Hemm, V. Rigau, J. Chevalier, M. C. Picot, L. Bauchet, H. El Fertit, M.-A. Rodriguez, L. Cif, N. Vayssiere, M. Zanca, et al. (2005)
J. Nucl. Med. 46, 1151-1157
   Abstract »    Full Text »    PDF »
Prolonged skin allograft survival by IL-10 gene-introduced CD4 T cell administration.
T. Miyamoto, T. Kaneko, M. Yamashita, Y. Tenda, M. Inami, A. Suzuki, S. Ishii, M. Kimura, K. Hashimoto, H. Shimada, et al. (2005)
Int. Immunol. 17, 759-768
   Abstract »    Full Text »    PDF »
The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.
K. Takacs, C. Du Roure, S. Nabarro, N. Dillon, J. H. McVey, Z. Webster, A. MacNeil, I. Bartok, C. Higgins, D. Gray, et al. (2004)
PNAS 101, 16298-16303
   Abstract »    Full Text »    PDF »
Impaired Germinal Center Maturation in Adenosine Deaminase Deficiency.
M. B. Aldrich, W. Chen, M. R. Blackburn, H. Martinez-Valdez, S. K. Datta, and R. E. Kellems (2003)
J. Immunol. 171, 5562-5570
   Abstract »    Full Text »    PDF »
Primer on Medical Genomics Part X: Gene Therapy.
S. J. Russell and K.-W. Peng (2003)
Mayo Clin. Proc. 78, 1370-1383
   Abstract »    PDF »
Gene Therapy for Renal Diseases: Its Potential and Limitation.
E. Imai (2003)
J. Am. Soc. Nephrol. 14, 1102-1104
   Full Text »    PDF »
Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.
L. M. Muul, L. M. Tuschong, S. L. Soenen, G. J. Jagadeesh, W. J. Ramsey, Z. Long, C. S. Carter, E. K. Garabedian, M. Alleyne, M. Brown, et al. (2003)
Blood 101, 2563-2569
   Abstract »    Full Text »    PDF »
What can cardiovascular gene transfer learn from genomics: and vice versa?.
T. H. Kim, K. A. Skelding, E. G. Nabel, and R. D. Simari (2002)
Physiol Genomics 11, 179-182
   Abstract »    Full Text »    PDF »
Recipient intramuscular cotransfection of naked plasmid transforming growth factor {beta}1 and interleukin 10 ameliorates lung graft ischemia-reperfusion injury.
N. Daddi, T. Suda, F. D'Ovidio, S. A. Kanaan, T. Tagawa, K. Grapperhaus, B. D. Kozower, J. H. Ritter, N. S Yew, T. Mohanakumar, et al. (2002)
J. Thorac. Cardiovasc. Surg. 124, 259-269
   Abstract »    Full Text »    PDF »
Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning.
A. Aiuti, S. Slavin, M. Aker, F. Ficara, S. Deola, A. Mortellaro, S. Morecki, G. Andolfi, A. Tabucchi, F. Carlucci, et al. (2002)
Science 296, 2410-2413
   Abstract »    Full Text »    PDF »
Gene Therapy for Cardiac Arrhythmias.
E. MARBAN, H.B. NUSS, and J.K. DONAHUE (2002)
Cold Spring Harb Symp Quant Biol 67, 527-532
   Abstract »    PDF »
T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation.
T. Ariga, N. Oda, K. Yamaguchi, N. Kawamura, H. Kikuta, S. Taniuchi, Y. Kobayashi, K. Terada, H. Ikeda, M. S. Hershfield, et al. (2001)
Blood 97, 2896-2899
   Abstract »    Full Text »    PDF »
Preselective gene therapy for Fabry disease.
G. Qin, T. Takenaka, K. Telsch, L. Kelley, T. Howard, T. Levade, R. Deans, B. H. Howard, H. L. Malech, R. O. Brady, et al. (2001)
PNAS
   Abstract »    Full Text »
Nonmyeloablative Immunosuppressive Regimen Prolongs In Vivo Persistence of Gene-Modified Autologous T Cells in a Nonhuman Primate Model.
C. Berger, M.-L. Huang, M. Gough, P. D. Greenberg, S. R. Riddell, and H.-P. Kiem (2001)
J. Virol. 75, 799-808
   Abstract »    Full Text »
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.
P. Tiberghien, C. Ferrand, B. Lioure, N. Milpied, R. Angonin, E. Deconinck, J.-M. Certoux, E. Robinet, P. Saas, B. Petracca, et al. (2001)
Blood 97, 63-72
   Abstract »    Full Text »    PDF »
Design of Retroviral Vectors and Helper Cells for Gene Therapy.
W.-S. Hu and V. K. Pathak (2000)
Pharmacol. Rev. 52, 493-512
   Abstract »    Full Text »    PDF »
Gene Therapy for Cardiovascular Disease.
S. L. Meyerson, C. L. Skelly, M. A. Curi, and L. B. Schwartz (2000)
Seminars in Cardiothoracic and Vascular Anesthesia 4, 289-300
   Abstract »    PDF »
Genetically Modified CD34+ Cells Exert a Cytotoxic Bystander Effect on Human Endothelial and Cancer Cells.
W. O. Arafat, E. Casado, M. Wang, R. D. Alvarez, G. P. Siegal, J. C. Glorioso, D. T. Curiel, and J. Gomez-Navarro (2000)
Clin. Cancer Res. 6, 4442-4448
   Abstract »    Full Text »    PDF »
Catalytic Nucleic Acids: From Lab to Applications.
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach (2000)
Pharmacol. Rev. 52, 325-348
   Abstract »    Full Text »    PDF »
Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins.
D. Chinnasamy, N. Chinnasamy, M. J. Enriquez, M. Otsu, R. A. Morgan, and F. Candotti (2000)
Blood 96, 1309-1316
   Abstract »    Full Text »    PDF »
Retroviral vectors.
K M Kurian, C J Watson, and A H Wyllie (2000)
Mol. Pathol. 53, 173-176
   Abstract »    Full Text »
Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector.
V. Dardalhon, S. Jaleco, C. Rebouissou, C. Ferrand, N. Skander, L. Swainson, P. Tiberghien, H. Spits, N. Noraz, and N. Taylor (2000)
Blood 96, 885-893
   Abstract »    Full Text »    PDF »
Echocardiographic Destruction of Albumin Microbubbles Directs Gene Delivery to the Myocardium.
R. V. Shohet, S. Chen, Y.-T. Zhou, Z. Wang, R. S. Meidell, R. H. Unger, and P. A. Grayburn (2000)
Circulation 101, 2554-2556
   Abstract »    Full Text »    PDF »
Expression of Herpes Simplex Virus ICP47 and Human Cytomegalovirus US11 Prevents Recognition of Transgene Products by CD8+ Cytotoxic T Lymphocytes.
C. Berger, S. Xuereb, D. C. Johnson, K. S. Watanabe, H.-P. Kiem, P. D. Greenberg, and S. R. Riddell (2000)
J. Virol. 74, 4465-4473
   Abstract »    Full Text »
THE IMPACT OF TISSUE ENGINEERING ON DENTISTRY.
B. J. BAUM and D. J. MOONEY (2000)
J Am Dent Assoc 131, 309-318
   Abstract »    Full Text »    PDF »
High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34+ cells.
R. E. Donahue, R. P. Wersto, J. A. Allay, B. A. Agricola, M. E. Metzger, A. W. Nienhuis, D. A. Persons, and B. P. Sorrentino (2000)
Blood 95, 445-452
   Abstract »    Full Text »    PDF »
Immunogenetics: changing the face of immunodeficiency.
A. M Jones and H. B Gaspar (2000)
J. Clin. Pathol. 53, 60-65
   Full Text »    PDF »
Gene therapy: lessons learnt from the past decade.
R. A Morgan and R M. Blaese (1999)
BMJ 319, 1310
   Full Text »
In Vivo Kinetics of Transduced Cells in Peripheral T Cell-Directed Gene Therapy: Role of CD8+ Cells in Improved Immunological Function in an Adenosine Deaminase (ADA)-SCID Patient.
N. Kawamura, T. Ariga, M. Ohtsu, I. Kobayashi, M. Yamada, A. Tame, H. Furuta, M. Okano, M. Egashira, N. Niikawa, et al. (1999)
J. Immunol. 163, 2256-2261
   Abstract »    Full Text »    PDF »
Deficient Cellular Immunity--Finding and Fixing the Defects.
P. D. Greenberg and S. R. Riddell (1999)
Science 285, 546-551
   Abstract »    Full Text »
Correction of Uroporphyrinogen Decarboxylase Deficiency (Hepatoerythropoietic Porphyria) in Epstein-Barr Virus-Transformed B-Cell Lines by Retrovirus-Mediated Gene Transfer: Fluorescence-Based Selection of Transduced Cells.
A. Fontanellas, F. Mazurier, F. Moreau-Gaudry, F. Belloc, C. Ged, and H. de Verneuil (1999)
Blood 94, 465-474
   Abstract »    Full Text »    PDF »
Natural Killer Cell-mediated Lysis of Autologous Cells Modified by Gene Therapy.
C. Liberatore, M. Capanni, N. Albi, I. Volpi, E. Urbani, L. Ruggeri, A. Mencarelli, F. Grignani, and A. Velardi (1999)
J. Exp. Med. 189, 1855-1862
   Abstract »    Full Text »    PDF »
One-Day Ex Vivo Culture Allows Effective Gene Transfer Into Human Nonobese Diabetic/Severe Combined Immune-Deficient Repopulating Cells Using High-Titer Vesicular Stomatitis Virus G Protein Pseudotyped Retrovirus.
V. I. Rebel, M. Tanaka, J.-S. Lee, S. Hartnett, M. Pulsipher, D. G. Nathan, R. C. Mulligan, and C. A. Sieff (1999)
Blood 93, 2217-2224
   Abstract »    Full Text »    PDF »
Transduction of Primitive Human Marrow and Cord Blood-Derived Hematopoietic Progenitor Cells With Adeno-Associated Virus Vectors.
S. Chatterjee, W. Li, C. A. Wong, G. Fisher-Adams, D. Lu, M. Guha, J. A. Macer, S. J. Forman, and K.K. Wong Jr (1999)
Blood 93, 1882-1894
   Abstract »    Full Text »    PDF »
Enhanced Retroviral Transduction of 5-Fluorouracil-Resistant Human Bone Marrow (Stem) Cells Using a Genetically Modified Packaging Cell Line.
J. Povey, N. Weeratunge, C. Marden, A. Sehgal, A. Thrasher, and C. Casimir (1998)
Blood 92, 4080-4089
   Abstract »    Full Text »    PDF »
Review : Gene Therapy: Applications to the Neurosciences and to Neurological Disease.
M. H. Tuszynski (1998)
Neuroscientist 4, 398-407
   Abstract »    PDF »
An Improved Retroviral Gene Transfer Technique Demonstrates Inhibition of CD4-CD8- Thymocyte Development by Kinase-Inactive ZAP-70.
T. Sugawara, V. Di Bartolo, T. Miyazaki, H. Nakauchi, O. Acuto, and Y. Takahama (1998)
J. Immunol. 161, 2888-2894
   Abstract »    Full Text »    PDF »
Case 18-1998- A 54-Day-Old Premature Girl with Respiratory Distress and Persistent Pulmonary Infiltrates.
F. S. Rosen and A. K. Bhan (1998)
N. Engl. J. Med. 338, 1752-1758
   Full Text »    PDF »
High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes Is Mediated by Transduction on Recombinant Fibronectin Fragments.
K. E. Pollok, H. Hanenberg, T. W. Noblitt, W. L. Schroeder, I. Kato, D. Emanuel, and D. A. Williams (1998)
J. Virol. 72, 4882-4892
   Abstract »    Full Text »    PDF »
Scaffold Attachment Region-Mediated Enhancement of Retroviral Vector Expression in Primary T Cells.
M. Agarwal, T. W. Austin, F. Morel, J. Chen, E. Bohnlein, and I. Plavec (1998)
J. Virol. 72, 3720-3728
   Abstract »    Full Text »    PDF »
Development of Improved Adenosine Deaminase Retroviral Vectors.
M. Onodera, D. M. Nelson, A. Yachie, G. J. Jagadeesh, B. A. Bunnell, R. A. Morgan, and R. M. Blaese (1998)
J. Virol. 72, 1769-1774
   Abstract »    Full Text »    PDF »
Adenosine Deaminase-deficient Mice Generated Using a Two-stage Genetic Engineering Strategy Exhibit a Combined Immunodeficiency.
M. R. Blackburn, S. K. Datta, and R. E. Kellems (1998)
J. Biol. Chem. 273, 5093-5100
   Abstract »    Full Text »    PDF »
Gene Therapy for Restenosis : Are We Ready?.
M. B. DeYoung and D. A. Dichek (1998)
Circ. Res. 82, 306-313
   Abstract »    Full Text »    PDF »
Primary Immunodeficiency Diseases in Adults.
S. H. Sicherer and J. A. Winkelstein (1998)
JAMA 279, 58-61
   Full Text »    PDF »
Successful Peripheral T-Lymphocyte-Directed Gene Transfer for a Patient With Severe Combined Immune Deficiency Caused by Adenosine Deaminase Deficiency.
M. Onodera, T. Ariga, N. Kawamura, I. Kobayashi, M. Ohtsu, M. Yamada, A. Tame, H. Furuta, M. Okano, S. Matsumoto, et al. (1998)
Blood 91, 30-36
   Abstract »    Full Text »    PDF »
Primary Immunodeficiency Diseases.
J. M. Puck (1997)
JAMA 278, 1835-1841
   Abstract »    PDF »
Immunopharmacology: Immunomodulation and Immunotherapy.
M. Ballow and R. Nelson (1997)
JAMA 278, 2008-2017
   Abstract »    PDF »
Gene therapy.
M. A. Kay, D. Liu, and P. M. Hoogerbrugge (1997)
PNAS 94, 12744-12746
   Abstract »    Full Text »    PDF »
Development of a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Cells.
K. Ito, Y. Ueda, M. Kokubun, M. Urabe, T. Inaba, H. Mano, H. Hamada, T. Kitamura, H. Mizoguchi, T. Sakata, et al. (1997)
Blood 90, 3884-3892
   Abstract »    Full Text »    PDF »
Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.
H. L. Malech, P. B. Maples, N. Whiting-Theobald, G. F. Linton, S. Sekhsaria, S. J. Vowells, F. Li, J. A. Miller, E. DeCarlo, S. M. Holland, et al. (1997)
PNAS 94, 12133-12138
   Abstract »    Full Text »    PDF »
Retroviral-Mediated Transfer of the Green Fluorescent Protein Gene Into Murine Hematopoietic Cells Facilitates Scoring and Selection of Transduced Progenitors In Vitro and Identification of Genetically Modified Cells In Vivo.
D. A. Persons, J. A. Allay, E. R. Allay, R. J. Smeyne, R. A. Ashmun, B. P. Sorrentino, and A. W. Nienhuis (1997)
Blood 90, 1777-1786
   Abstract »    Full Text »    PDF »
Stem Cell-Based Gene Therapy.
C. Bagnis and P. Mannoni (1997)
Oncologist 2, 196-202
   Full Text »    PDF »
Efficient In Vivo Marking of Primary CD4+ T Lymphocytes in Nonhuman Primates Using a Gibbon Ape Leukemia Virus-Derived Retroviral Vector.
B. A. Bunnell, M. Metzger, E. Byrne, R. A. Morgan, and R. E. Donahue (1997)
Blood 89, 1987-1995
   Abstract »    Full Text »    PDF »
Retroviral-Mediated Gene Transfer of gp91phox Into Bone Marrow Cells Rescues Defect in Host Defense Against Aspergillus fumigatus in Murine X-Linked Chronic Granulomatous Disease.
H. Bjorgvinsdottir, C. Ding, N. Pech, M. A. Gifford, L. L. Li, and M. C. Dinauer (1997)
Blood 89, 41-48
   Abstract »    Full Text »    PDF »
Gene Transfer to Hematopoietic Cells.
M. K. Brenner (1996)
N. Engl. J. Med. 335, 337-339
   Full Text »    PDF »
Somatic gene therapy.
J. Dorin (1996)
BMJ 312, 323-324
   Full Text »
Modest Success for Gene Therapy in Immunodeficiency.
(1995)
Journal Watch Dermatology 1995, 14
   Full Text »
MODEST SUCCESS FOR GENE THERAPY IN IMMUNODEFICIENCY.
(1995)
Journal Watch (General) 1995, 4
   Full Text »
Transfer of Genes to Humans: Early Lessons and Obstacles to Success.
R. G. Crystal (1995)
Science 270, 404-410
   Abstract »    PDF »
The Use of Enzyme Therapy to Regulate the Metabolic and Phenotypic Consequences of Adenosine Deaminase Deficiency in Mice. DIFFERENTIAL IMPACT ON PULMONARY AND IMMUNOLOGIC ABNORMALITIES.
M. R. Blackburn, M. Aldrich, J. B. Volmer, W. Chen, H. Zhong, S. Kelly, M. S. Hershfield, S. K. Datta, and R. E. Kellems (2000)
J. Biol. Chem. 275, 32114-32121
   Abstract »    Full Text »    PDF »
Preselective gene therapy for Fabry disease.
G. Qin, T. Takenaka, K. Telsch, L. Kelley, T. Howard, T. Levade, R. Deans, B. H. Howard, H. L. Malech, R. O. Brady, et al. (2001)
PNAS 98, 3428-3433
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)